SCHEMBL3309516

SCHEMBL3309516

Cc1cc(C(=O)O)cc(Br)c1Cl

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TTR P02766 3/20 0.52
TPMT P51580 4/20 0.45
HCAR1 Q9BXC0 2/20 0.39
GPR35 Q9HC97 1/20 0.39
MRGPRX4 Q96LA9 1/20 0.39
KDM4E B2RXH2 1/20 0.38
ALDH1A1 P00352 1/20 0.38
THRA P10827 1/20 0.37
THRB P10828 1/20 0.37
DAO P14920 1/20 0.37
ALOX15 P16050 2/20 0.37
TSHR P16473 2/20 0.37
MYC P01106 1/20 0.37
ESR1 P03372 1/20 0.37
PTPN7 P35236 1/20 0.37
HSD17B10 Q99714 1/20 0.37
CA12 O43570 1/20 0.37
CA1 P00915 1/20 0.37
CA2 P00918 1/20 0.37
CA7 P43166 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4507939 0.85 TPMT (0.54) TTRTPMTHCAR1GPR35MRGPRX4
SCHEMBL3307814 0.84 NPC1 (0.42) TTRALDH1A1ALOX15TSHRHSD17B10
SCHEMBL15425304 0.79 CA12 (0.46) KDM4EALDH1A1TSHRHSD17B10CA12
SCHEMBL29710249 0.79 TTR (0.56) TTRTPMTHCAR1GPR35KDM4E
SCHEMBL5631374 0.79 TTR (0.56) TTRTPMTHCAR1GPR35KDM4E
SCHEMBL15796379 0.79 TTR (0.56) TTRTPMTHCAR1GPR35KDM4E
SCHEMBL20094086 0.78 CA12 (0.52) TTRTPMTHCAR1GPR35MRGPRX4
SCHEMBL27461043 0.78 TPMT (0.46) TTRTPMTHCAR1GPR35MRGPRX4
SCHEMBL25977571 0.78 TTR (0.59) TTRTPMTHCAR1GPR35KDM4E
SCHEMBL8779295 0.78 TTR (0.54) TTRTPMTHCAR1GPR35KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20220315565-A1 INHIBITING FATTY ACID SYNTHASE (FASN) FORMA THERAPEUTICS, INC. 2022-10-06 US disclosed
US-11299484-B2 Inhibiting fatty acid synthase (FASN) FORMA THERAPEUTICS, INC. (US) 2022-04-12 US disclosed
CN-113329748-A Inhibition of Fatty Acid Synthase (FASN) 福马治疗股份有限公司 2021-08-31 CN disclosed
US-20210024508-A1 INHIBITING FATTY ACID SYNTHASE (FASN) FORMA THERAPEUTICS, INC. 2021-01-28 US disclosed
US-10875848-B2 Inhibiting fatty acid synthase (FASN) FORMA THERAPEUTICS, INC. (US) 2020-12-29 US disclosed
US-20200115368-A1 INHIBITING FATTY ACID SYNTHASE (FASN) FORMA THERAPEUTICS, INC. 2020-04-16 US disclosed
EP-3636637-A1 INHIBITING FATTY ACID SYNTHASE (FASN) Forma Therapeutics, Inc. (US) 2020-04-15 EP disclosed
EP-3636637-A1 INHIBITING FATTY ACID SYNTHASE (FASN) Forma Therapeutics, Inc. (US) 2020-04-15 EP disclosed
US-20100113411-A1 Selected CGRP antagonists, processes for preparing them and their use as pharmaceutical compositions BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) 2010-05-06 US disclosed
US-7595312-B2 Selected CGRP antagonists, processes for preparing them and their use as pharmaceutical compositions BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) 2009-09-29 US disclosed
EP-1558600-B1 SELECTED CGRP ANTAGONISTS, METHOD FOR PRODUCTION AND USE THEREOF AS MEDICAMENT BOEHRINGER INGELHEIM PHARMA (DE) 2008-05-07 EP disclosed
US-20060079504-A1 Selected CGRP antagonists, processes for preparing them and their use as pharmaceutical compositions BOEHRINGER INGELHEIM PHARMA GMBH & CO., KG (DE) 2006-04-13 US disclosed
CN-1708493-A Selected CGRP antagonists, method for production and use thereof as medicament BOEHRINGER INGELHEIM PHARMA (DE) 2005-12-14 CN disclosed
EP-1558600-A1 SELECTED CGRP ANTAGONISTS, METHOD FOR PRODUCTION AND USE THEREOF AS MEDICAMENT BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) 2005-08-03 EP disclosed
WO-2004037810-A1 SELECTED CGRP ANTAGONISTS, METHOD FOR PRODUCTION AND USE THEREOF AS MEDICAMENT BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) 2004-05-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10875848-B2 Inhibiting fatty acid synthase (FASN) FASN, SCD, FADS1 TTR 2183/4885TPMT 1614/4885HCAR1 824/4885
US-20210024508-A1 INHIBITING FATTY ACID SYNTHASE (FASN) FASN, SCD, FADS1 TTR 2183/4885TPMT 1614/4885HCAR1 824/4885
US-20100113411-A1 Selected CGRP antagonists, processes for preparing them and their use as pharmaceutical compositions CALCRL, CALCR, CALCA TTR 1227/4885TPMT 2139/4885HCAR1 282/4885
US-20200115368-A1 INHIBITING FATTY ACID SYNTHASE (FASN) FASN, SCD, FADS1 TTR 2183/4885TPMT 1614/4885HCAR1 824/4885
US-20060079504-A1 Selected CGRP antagonists, processes for preparing them and their use as pharmaceutical compositions CALCRL, CALCR, CALCA TTR 1227/4885TPMT 2139/4885HCAR1 282/4885
US-20220315565-A1 INHIBITING FATTY ACID SYNTHASE (FASN) FASN, SCD, FADS1 TTR 2183/4885TPMT 1614/4885HCAR1 824/4885
US-11299484-B2 Inhibiting fatty acid synthase (FASN) FASN, SCD, FADS1 TTR 2183/4885TPMT 1614/4885HCAR1 824/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.